Share This Page
Suppliers and packagers for generic pharmaceutical drug: netupitant; palonosetron hydrochloride
✉ Email this page to a colleague
netupitant; palonosetron hydrochloride
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718 | NDA | Helsinn Therapeutics (U.S.), Inc. | 69639-101-01 | 1 BLISTER PACK in 1 CARTON (69639-101-01) / 1 CAPSULE in 1 BLISTER PACK | 2014-10-13 |
| Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718 | NDA | Helsinn Therapeutics (U.S.), Inc. | 69639-101-04 | 2 BLISTER PACK in 1 CARTON (69639-101-04) / 2 CAPSULE in 1 BLISTER PACK | 2014-10-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for generic pharmaceutical drug: netupitant; palonosetron hydrochloride
Netupitant and Palonosetron Hydrochloride Suppliers: Who Makes the Key Drug Substances and Finished Products?
Executive summary: Netupitant and palonosetron hydrochloride are supplied for clinical and commercial use through a mix of API manufacturers and branded generic/finished-dose contract suppliers. The netupitant supply chain centers on specialized small-molecule API capabilities and solvent-free or controlled-process synthesis. Palonosetron hydrochloride has a broader set of API and salt-form manufacturing suppliers due to repeat demand across oncology and emetology regimens. Procurement typically requires qualification for residual solvents, particle size, genotoxic impurities, and controlled substance-of-interest impurity profiles tied to regulatory dossiers.
What suppliers produce netupitant (API) for pharmaceutical use?
Netupitant is typically sourced as an API under GMP for fixed-dose antiemetic combinations used with other agents in chemotherapy-induced nausea and vomiting (CINV) prophylaxis. Netupitant procurement is usually handled at two levels: direct API supply (GMP batches) and finished-dose contract manufacturing for combo products.
How many netupitant API suppliers exist in practice?
Market supply is concentrated. Netupitant is not a widely commodity-produced API, so buyer options tend to be limited to manufacturers with established capabilities for substituted small-molecule synthesis and validated impurity control.
What technical specs do netupitant API suppliers need to meet?
Netupitant API specifications used by downstream manufacturers commonly require:
- Confirmed polymorphic/solid-state form per dossier strategy
- Residual solvent limits and water content controls
- Tight impurity control for route-specific related compounds
- Genotoxic impurity controls (strategy-based, not generic)
- Trace metal limits and particle size targets for downstream blending
What suppliers produce palonosetron hydrochloride (API) for pharmaceutical use?
Palonosetron hydrochloride is a more “repeat use” API across CINV regimens because palonosetron is used in multiple fixed-dose and clinician-administered settings.
Which manufacturing form dominates: palonosetron HCl salt?
Procurement is usually centered on the hydrochloride salt form for dose accuracy and stability in injectable and oral-support formulations. Many suppliers support multiple presentations, but the API salt form is the anchor.
What technical specs do palonosetron HCl API suppliers need to meet?
Downstream formulation and drug product manufacturers typically require:
- Salt assay and water content targets
- Related substances consistent with approved method
- Particle size and flow properties for sterile fill finishing chains
- Ongoing stability compatibility testing inputs
Who supplies finished-dose antiemetic combinations containing netupitant and palonosetron?
In practice, buyers often source finished dosage forms rather than only APIs, depending on whether they are building a product pipeline or securing commercial supply. Finished-dose suppliers cover tablets and other presentation types aligned with regulatory approvals and commercial demand.
Which CINV combination product supply chains dominate netupitant + palonosetron?
The combination is used in standard-of-care CINV prophylaxis regimens. Supply chains typically involve:
- API supply for netupitant and palonosetron HCl
- Formulation development package transfer (if the buyer is contract-manufacturing)
- Tableting/blending with strict content uniformity controls
- For injectables, sterile process validation and container closure system qualification
What contract manufacturing organizations (CMOs) can handle netupitant plus palonosetron drug products?
CMOs typically offer:
- Solid oral dose manufacturing (blending, granulation if needed, compression, coating)
- Process development support for content uniformity and dissolution
- Packaging line qualification and serialization support
- Quality agreements and batch release testing support
What CMO capabilities matter most for this API pair?
- Controlled impurity management and route qualification alignment with dossier specs
- Strong analytical method transfer capability for both APIs and impurities
- Robust change control for supplier swaps (form, seed, raw material lot release)
- Experience with both highly controlled salts (palonosetron HCl) and less-commodity substituted small molecules (netupitant)
Which countries and manufacturing regions supply most netupitant and palonosetron APIs?
Netupitant and palonosetron HCl APIs are sourced globally, with concentration in regions that support:
- High-reliability GMP manufacturing
- Established capability for small-molecule impurity profiling
- Documented regulatory track records for dossier-supportable APIs
Procurement teams typically evaluate:
- Regulatory inspection history
- Documentation strength (DMFs, CEPs, validation packages)
- Lead-time stability and batch-to-batch consistency
What are the most common supplier qualification barriers for netupitant and palonosetron?
The main friction points are not pricing. They are validation and dossier alignment:
- Method transfer difficulty and impurity profile reconciliation
- Solid form verification and acceptance criteria mismatch
- Residual solvent/genotoxic impurity strategy mismatches
- Particle size and blending performance issues affecting uniformity
How should buyers structure API supplier risk management for this combination?
Procurement programs for netupitant plus palonosetron typically implement:
- Dual-sourcing for both APIs where feasible
- Long lead-time planning for initial qualification and stability bridging
- Supplier change control gates tied to analytical comparability
- Inventory planning based on lead-time variability and inspection cycles
How does the supplier landscape differ between netupitant and palonosetron hydrochloride?
- Netupitant has a more concentrated, specialized supplier set due to lower commodity demand and more route-specific impurity control needs.
- Palonosetron hydrochloride has more supplier presence because of broader therapeutic use and repeat manufacturing demand.
- For either API, buyers still face dossier alignment and impurity control requirements that reduce the effective number of “qualified” vendors versus the raw number of “available” vendors.
What does due diligence look like for netupitant and palonosetron suppliers?
A supplier qualification checklist that is consistently used in this class includes:
- DMF or equivalent regulatory documentation availability
- GMP certificate coverage for the relevant manufacturing site and process
- Batch analysis and impurity trend data
- Residual solvent and elemental impurity certificates
- Genotoxic impurity risk dossier readiness (strategy and controls)
- Real stability data aligned to intended retest periods
- Audit history and deviation/CAPA summary
Key Takeaways
- Netupitant API supply is specialized and concentrated, making qualification and impurity-profile alignment the dominant procurement constraint.
- Palonosetron hydrochloride API has a broader supplier base, but salt-form control and impurity methods still drive effective vendor counts.
- For finished-dose production, CMOs and drug product manufacturers depend on supplier-controlled quality systems to hit dissolution/content uniformity targets and maintain dossier-consistent impurity profiles.
- The practical supplier landscape for both APIs narrows after QA qualification, change-control feasibility review, and dossier method comparability checks.
FAQs
- What documentation do netupitant API suppliers provide to support regulatory filings (DMF/CEP)?
- How do palonosetron hydrochloride salt-form and water content specifications affect manufacturing release?
- What impurity trends commonly cause batch rejection when switching netupitant API suppliers?
- Which CMO process controls are most critical for content uniformity in netupitant and palonosetron tablets?
- What change control steps are typically required when swapping palonosetron HCl API lots or suppliers?
References
- European Medicines Agency. “Guideline on the requirements for quality documentation concerning biological active substances.” EMA.
- U.S. Food and Drug Administration. “Guidance for Industry: ANDAs: Impurities in Drug Substances and Drug Products: Chemistry, Manufacturing, and Controls Information.” FDA.
- International Council for Harmonisation. “ICH Q3A(R2): Impurities in New Drug Substances.” ICH.
- International Council for Harmonisation. “ICH Q3B(R2): Impurities in New Drug Products.” ICH.
- International Council for Harmonisation. “ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.” ICH.
More… ↓
